Label-free Array Systems Market Size, Share & Analysis Report, 2024-2033
The global label-free array systems market size was exhibited at USD 455.93 million in 2023 and is projected to hit around USD 933.59 million by 2033, growing at a CAGR of 7.43% during the forecast period of 2024 to 2033.
Key Takeaways:
Label-free Array System Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 455.93 Million |
| Market Size by 2033 | USD 933.59 Million |
| Growth Rate From 2024 to 2033 | CAGR of 7.43% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Type, Application, End-user, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Illumina; Inc.; Thermo Fisher Scientific; Inc.; Agilent Technologies; Inc.; PerkinElmer; Inc.; Merck KGaA; Danaher Corporation; Bio-Rad Laboratories; Inc.; F. Hoffmann-La Roche AG; Becton; Dickinson and Company; Sartorius AG. |
The increasing demand for personalized medicine, as well as a variety of other factors such as the prevalence of chronic diseases, increased research activities in biomedical science, the need for high-throughput screening, and the demand for cost-effective and efficient systems. In June 2023, a scientific report published by Springer Nature Limited stated the development of a label-free multiplex electrochemical immunosensor for detecting the characteristics of Pompe, Gaucher and Krabbe disease. The research concluded that immunosensor showcased good sensitivity and is applicable in POC testing settings for the early diagnosis of lysosomal storage disorders. Hence, increasing applications are likely to have a positive impact on the demand for a label-free array.
Additionally, government funding for research activities and the emergence of new technologies such as nanotechnology are also contributing to market growth. Companies such as Bruker are at the forefront of these developments. For instance, in June 2018 the company launched new systems such as the Sierra SPR-32 system, which is equipped with R3 software that provides high sensitivity and the highest SPR throughput. This software increases the instrument's precision and productivity, and the label-free strategies will help accelerate the process of taking chemical entities to clinical trials.
Moreover, the COVID-19 pandemic challenged the existing diagnostics tools and compelled companies to develop the product in the line of infection detection. For instance, in January 2023, professionals from various institutions conducted collaborative research to develop an interdigitated microelectrode array-based impedimetric immunosensor to identify and monitor COVID-19 antibodies. The immunosensor is a label-free technology and is suitable for point-of-care applications. The COVID-19 pandemic encouraged companies and researchers to develop a cost-efficient and accurately label-free array-based diagnostic tool to detect the infection.
Along with that, a number of companies have entered the market for label-free array systems. For instance, in November 2018, Agilent Technologies acquired ACEA Biosciences, a company that develops and manufactures label-free array systems for the detection and analysis of biomolecules. This acquisition was likely made in order to expand Agilent's portfolio of products and services in the label-free array systems market. This highlights the growing demand for label-free detection methods in the field of biological and biomedical research.
Segments Insights:
Type Insights
Surface plasmon resonance held the major share of the label-free array system market in 2023 with 34.96%. The largest market share is attributed to high R&D investments by prominent market players. In addition, the increasing risk of lifestyle-related chronic diseases is anticipated to drive clinical urgency to incorporate these systems, thus propelling the label-free array system market over the forecast period. For instance, Sartorius offers a range of solutions to meet the global demand for vaccine research, antibody fragment characterization, and whole-cell biologics.
Along with that, bio-layer interferometry is widely employed in numerous applications. However, the primary application is considered to be drug discovery and development. It is a highly preferable technique, since it is fully automated, fast, and requires minimal intervention by the users. It is also an optimal approach for measuring the interactions between macromolecular through assessing the interference patterns.
Application Insights
The drug discovery segment showcased a significant growth rate during the forecasted period with 34.96% of the market share in 2023. The label-free analytical approach allows real-time and high-resolution monitoring of kinetic interaction. Accurate data on kinetics is important in drug development since it assists in identifying and isolating therapeutic molecules for their target. This can shorten the timespan to discover, and streamline the selection of ideal candidates for drugs with optimal chances of success downstream.
Protein interface analysis is expected to capture a considerable market share in 2023. Owing to the limitations of labeling strategies, the development of reliable, sensitive, and label-free arrays is drawing substantial attention. For instance, Proteon XPR36 by Bio-Rad is a protein interaction array system based on SPR technology to identify and monitor interactions of biomolecular for assessing label-free interactions.
End-user Insight
Pharmaceutical and biotechnology companies segment is expected to have the largest proportion of the market share in 2023 with 45.0%. The major firms are also investing in R&D to provide products and services for the early detection and management of chronic diseases. As a result, organizations are embracing improved analytical technologies, propelling the worldwide label-free array system market. The assessment of biomolecular interactions through label-free array systems along with the study of drug interactions holds great importance in the pharmaceutical segment.
Regional Insights
North America accounted for the largest share of the market in 2023 with 48.0%, owing to the presence of major companies, extensive government funding, and an increase in research activities in the region. In addition, the use of antibody characterization in research programs by universities in the U.S. and Canada. These have accelerated the progress in the biotechnology sector, thereby increasing the demand for high-throughput analytical technology solutions in laboratory workflows. North America is expected to maintain its market dominance over the forecast period owing to the rapid adoption of advanced technological solutions, high investments in R&D, and rising wages of skilled personnel in this region.
The markets within Asia Pacific are projected to grow at the fastest rate during the forecast period, which can be attributed to the increasing interest of key global players in capturing regional revenue share by expanding into emerging markets. Global investors are increasingly investing in China and India due to economic developments. Similarly, regional players are strengthening their presence in the global label-free array system market.
Some of the prominent players in the Label-free array systems market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global label-free array systems market.
Type Scope
Application Scope
End-user Scope
By Region
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.5. Market Restraint Analysis
3.6. Penetration and Growth Prospect Mapping 2022
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Label-free Array Systems Market: Type Movement Analysis
4.2. Surface Plasmon Resonance
4.2.1. Surface Plasmon Resonance Market, 2021 - 2033
4.3. Bio-layer Interferometry
4.3.1. Bio-layer Interferometry Market, 2021 - 2033
4.4. Cellular Dielectric Spectroscopy
4.4.1. Cellular Dielectric Spectroscopy Market, 2021 - 2033
Chapter 5. Application Business Analysis
5.1. Label-free Array Systems Market: Application Movement Analysis
5.2. Drug Discovery
5.2.1. Drug Discovery Market, 2021 - 2033
5.3. Protein Interface Analysis
5.3.1. Protein Interface Analysis Market, 2021 - 2033
5.4. Antibody Characterization
5.4.1. Antibody Characterization Market, 2021 - 2033
5.5. Others
5.5.1. Others Market, 2021 - 2033
Chapter 6. End-user Business Analysis
6.1. Label-free Array Systems Market: End-user Movement Analysis
6.2. Pharmaceutical & Biotechnology Companies
6.2.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033
6.3. Academic & Research Institutes
6.3.1. Academic & Research Institutes Market, 2021 - 2033
6.4. CRO
6.4.1. CRO Market, 2021 - 2033
6.5. Others
6.5.1. Others Market, 2021 - 2033
Chapter 7. Regional Business Analysis
7.1. Label-free Array Systems Market Share By Region, 2024 & 2033
7.2. North America
7.2.1. SWOT Analysis
7.2.2. North America Label-free array systems Market, 2021 - 2033
7.2.3. U.S.
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Reimbursement Scenario
7.2.3.6. U.S. Label-free array systems Market, 2021 - 2033
7.2.4. Canada
7.2.4.1. Key Country Dynamics
7.2.4.2. Target Disease Prevalence
7.2.4.3. Competitive Scenario
7.2.4.4. Regulatory Framework
7.2.4.5. Reimbursement Scenario
7.2.4.6. Canada Label-free array systems Market, 2021 - 2033
7.3. Europe
7.3.1. SWOT Analysis
7.3.2. Europe Label-free array systems Market, 2021 - 2033
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Reimbursement Scenario
7.3.3.6. Germany Label-free array systems Market, 2021 - 2033
7.3.4. UK
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. Reimbursement Scenario
7.3.4.6. UK Label-free array systems Market, 2021 - 2033
7.3.5. France
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Reimbursement Scenario
7.3.5.6. France Label-free array systems Market, 2021 - 2033
7.3.6. Italy
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Reimbursement Scenario
7.3.6.6. Italy Label-free array systems Market, 2021 - 2033
7.3.7. Spain
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Reimbursement Scenario
7.3.7.6. Spain Label-free array systems Market, 2021 - 2033
7.3.8. Denmark
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Reimbursement Scenario
7.3.8.6. Denmark Label-free array systems Market, 2021 - 2033
7.3.9. Sweden
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Reimbursement Scenario
7.3.9.6. Sweden Label-free array systems Market, 2021 - 2033
7.3.10. Norway
7.3.10.1. Key Country Dynamics
7.3.10.2. Target Disease Prevalence
7.3.10.3. Competitive Scenario
7.3.10.4. Regulatory Framework
7.3.10.5. Reimbursement Scenario
7.3.10.6. Norway Label-free array systems Market, 2021 - 2033
7.4. Asia Pacific
7.4.1. SWOT Analysis
7.4.2. Asia Pacific Label-free array systems Market, 2021 - 2033
7.4.3. Japan
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. Reimbursement Scenario
7.4.3.6. Japan Label-free array systems Market, 2021 - 2033
7.4.4. China
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. Reimbursement Scenario
7.4.4.6. China Label-free array systems Market, 2021 - 2033
7.4.5. India
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Reimbursement Scenario
7.4.5.6. India Label-free array systems Market, 2021 - 2033
7.4.6. South Korea
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Reimbursement Scenario
7.4.6.6. South Korea Label-free array systems Market, 2021 - 2033
7.4.7. Australia
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. Reimbursement Scenario
7.4.7.6. Australia Label-free array systems Market, 2021 - 2033
7.4.8. Thailand
7.4.8.1. Key Country Dynamics
7.4.8.2. Target Disease Prevalence
7.4.8.3. Competitive Scenario
7.4.8.4. Regulatory Framework
7.4.8.5. Reimbursement Scenario
7.4.8.6. Thailand Label-free array systems Market, 2021 - 2033
7.5. Latin America
7.5.1. SWOT Analysis
7.5.2. Latin America Label-free array systems Market, 2021 - 2033
7.5.3. Brazil
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Reimbursement Scenario
7.5.3.6. Brazil Label-free array systems Market, 2021 - 2033
7.5.4. Mexico
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Reimbursement Scenario
7.5.4.6. Mexico Label-free array systems Market, 2021 - 2033
7.5.5. Argentina
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Competitive Scenario
7.5.5.4. Regulatory Framework
7.5.5.5. Reimbursement Scenario
7.5.5.6. Argentina Label-free array systems Market, 2021 - 2033
7.6. MEA
7.6.1. SWOT Analysis
7.6.2. MEA Label-free array systems Market, 2021 - 2033
7.6.3. South Africa
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Reimbursement Scenario
7.6.3.6. South Africa Label-free array systems Market, 2021 - 2033
7.6.4. Saudi Arabia
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. Reimbursement Scenario
7.6.4.6. Saudi Arabia Label-free array systems Market, 2021 - 2033
7.6.5. UAE
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Reimbursement Scenario
7.6.5.6. UAE Label-free array systems Market, 2021 - 2033
7.6.6. Kuwait
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Competitive Scenario
7.6.6.4. Regulatory Framework
7.6.6.5. Reimbursement Scenario
7.6.6.6. Kuwait Label-free array systems Market, 2021 - 2033
Chapter 8. Competitive Landscape
8.1. Participant’s overview
8.2. Financial performance
8.3. Participant categorization
8.3.1. Market Leaders
8.3.2. Label-free Array Systems Market Share Analysis, 2024
8.3.3. Company Profiles
8.3.3.1. Illumina, Inc.,
8.3.3.2. Thermo Fisher Scientific, Inc.
8.3.3.3. Agilent Technologies, Inc.
8.3.3.4. PerkinElmer, Inc.
8.3.3.5. Merck KGaA
8.3.3.6. Danaher Corporation
8.3.3.7. Bio-Rad Laboratories, Inc.
8.3.3.8. F. Hoffmann-La Roche AG
8.3.3.9. Becton, Dickinson and Company
8.3.3.10. Sartorius AG.
8.3.4. Strategy Mapping
8.3.4.1. Expansion
8.3.4.2. Acquisition
8.3.4.3. Collaborations
8.3.4.4. Product/Service Launch
8.3.4.5. Partnerships
8.3.4.6. Others
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers